STUDY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLUL

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of this study is to assess if a new drug, sorafenib, is an effective treatment for patients with liver cancer. Subjects in this study received either sorafenib or placebo (a tablet that looks identical to sorafenib but contains no active drug). To date, over 8787 cancer patients have taken sorafenib either as a lone treatment or together with other chemotherapy drugs for several different types of cancer. Following a review of the data collected from this study so far, a significant difference was noticed in the overall survival between patients receiving sorafenib and patients receiving placebo (sugar pill that looks like sorafenib). Those patients taking sorafenib lived longer on average compared to patients taking placebo. As a result the crossover phase of the study has begun where subjects taking sorafenib have been offered the option to continue taking sorafenib. Subjects taking placebo have been offered the option to begin taking sorafenib. This crossover phase of the study will continue until an alternative supply of sorafenib treatment outside of the study is made available.'